2. Signaling Pathways
  3. Metabolic Enzyme/Protease
  4. Phosphodiesterase (PDE)

Phosphodiesterase (PDE)

Phosphodiesterase (PDE)

Related Products

PDF 4.17 MB

Phosphodiesterase (PDE) is any enzyme that breaks a phosphodiester bond. Usually, people speaking of phosphodiesterase are referring to cyclic nucleotide phosphodiesterases, which have great clinical significance and are described below. However, there are many other families of phosphodiesterases, including phospholipases C and D, autotaxin, sphingomyelin phosphodiesterase, DNases, RNases, and restriction endonucleases, as well as numerous less-well-characterized small-molecule phosphodiesterases. The cyclic nucleotide phosphodiesterases comprise a group of enzymes that degrade the phosphodiester bond in the second messenger molecules cAMP and cGMP. They regulate the localization, duration, and amplitude of cyclic nucleotide signaling within subcellular domains. PDEs are therefore important regulators ofsignal transduction mediated by these second messenger molecules.

Phosphodiesterase (PDE) Isoform Specific Products:

Phosphodiesterase (PDE) Isoform Comparison
Cat. No. Product Name Effect Purity Chemical Structure
  • HY-101803
    CP671305
    		Inhibitor 99.95%
    CP671305 is a potent, orally active, selective inhibitor of phosphodiesterase-4-D, and possesses high activities.
    CP671305
  • HY-B0004S
    Doxofylline-d6
    		Inhibitor 99.67%
    Doxofylline-d6 is the deuterium labeled Doxofylline. Doxofylline is an antagonist of adenosine A1 receptor which also inhibits phosphodiesterase IV.
    Doxofylline-d<sub>6</sub>
  • HY-108619
    Gisadenafil besylate
    		Inhibitor 99.74%
    Gisadenafil besylate (UK 369003-26) is a specific, orally active phosphodiesterase 5 (PDE5) inhibitor with an IC50 of 3.6 nM and prevents degradation of cyclic guanosine monophosphate (cGMP).
    Gisadenafil besylate
  • HY-15025AR
    Sildenafil citrate (Standard)
    		Inhibitor
    Sildenafil (citrate) (Standard) is the analytical standard of Sildenafil (citrate). This product is intended for research and analytical applications. Sildenafil citrate is a potent phosphodiesterase type 5 (PDE5) inhibitor with IC50 of 5.22 nM.
    Sildenafil citrate (Standard)
  • HY-14550A
    PDE10-IN-5
    		Inhibitor 99.92%
    PDE10-IN-5 is a phosphodiesterase 10 (PDE 10) inhibitor, can be used for researching certain central nervous system (CNS) disorders.
    PDE10-IN-5
  • HY-12318G
    IBMX (GMP)
    		Inhibitor
    IBMX (3-Isobutyl-1-methylxanthine) (GMP) is IBMX (HY-12318) produced by using GMP guidelines. GMP small molecules works appropriately as an auxiliary reagent for cell therapy manufacture. IBMX is a broad-spectrum phosphodiesterase (PDE) inhibitor.
    IBMX (GMP)
  • HY-12913
    AMG 579
    		Inhibitor 98.95%
    AMG 579 is a potent, selective, and efficacious inhibitor of phosphodiesterase 10A (PDE10A) with an IC50 of 0.1 nM.
    AMG 579
  • HY-B0204S1
    Pimobendan-d3
    		Inhibitor 99.43%
    Pimobendan-d3 (UD-CG115-d3) is deuterium labeled Pimobendan (HY-B0204). Pimobendan (UD-CG115) is a selective inhibitor of PDE3 with IC50 of 0.32 μM.
    Pimobendan-d<sub>3</sub>
  • HY-114303
    CM-675
    		Inhibitor 99.53%
    CM-675 is a dual phosphodiesterase 5 (PDE5) and class I histone deacetylases-selective inhibitor, with IC50 values of 114 nM and 673 nM for PDE5 and HDAC1, respectively. CM-675 has potential to treat Alzheimer’s disease.
    CM-675
  • HY-104028A
    BAY 73-6691 racemate
    		Inhibitor 99.86%
    BAY 73-6691 racemate is a phosphodiesterase 9 inhibitor extracted from patent WO 2017070293 A1.
    BAY 73-6691 racemate
  • HY-14826
    Tilivapram
    		Inhibitor 99.96%
    Tilivapram (AVE8112) is an orally active PDE4 inhibitor with procognitive effects. Tilivapram exhibits in vivo efficacy and improves processing speed and psychomotor speed. Oral administration of tilivapram may induce dose-related adverse reactions such as nausea and dizziness, but transdermal delivery enables slow, controlled elevation of plasma concentrations, thereby significantly reducing gastrointestinal discomfort and dizziness. Tilivapram is applicable to research related to neuropsychiatric disorders.
    Tilivapram
  • HY-124775
    (S)-C33
    		Inhibitor 99.46%
    (S)-C33 is a potent and selective PDE9 (phosphodiesterase-9) inhibitor, with an IC50 of 11 nM. (S)-C33 can be used for central nervous system diseases and diabetes research.
    (S)-C33
  • HY-133712
    Yonkenafil
    		Inhibitor 99.52%
    Yonkenafil (Tunodafil), a novel phosphodiesterase 5 (PDE5) inhibitor, is effective in reducing cerebral infarction, neurological deficits, edema, and neuronal damage in the infarcted area. Yonkenafil may improve cognitive function by modulating neurogenesis and has a potential therapeutic effect on Alzheimer's disease.
    Yonkenafil
  • HY-122641
    Deltasonamide 1
    		Inhibitor 99.15%
    Deltasonamide 1 is a PDE6δ-KRas inhibitor. Deltasonamide 1 can inhibit PDE6δ-KRas with a KD of 203 pM. Deltasonamide 1 can be used for the research of tumors.
    Deltasonamide 1
  • HY-401913
    endo CNTinh-03
    		Inhibitor 99.96%
    Endo CNTinh-03 is inhibitor for the elevation of cAMP and cGMP induced by agonist, such as G protein-coupled receptors, adenylate cyclase, and guanylate cyclase (IC50 is 4 μM). Endo CNTinh-03 inhibits cholera toxin- and Escherichia coli (STa) toxin- induced CFTR chloride current, ameliorates secretory diarrhea in mouse models, and prevents cyst growth in polycystic kidney disease model.
    endo CNTinh-03
  • HY-169981
    PDE4-IN-24
    		Inhibitor 99.44%
    PDE4-IN-24 (compoud 14h) is a potent inhibitor of PDE4D with the IC50 of 0.57 nM and >4100-fold selectivity over other PDE families. PDE4-IN-24 plays an important role in inflammatory disease.
    PDE4-IN-24
  • HY-122641B
    Deltasonamide 2 TFA
    		Inhibitor 99.67%
    Deltasonamide 2 TFA is competitive, high affinity PDEδ inhibitor with a Kd of ~385 pM.
    Deltasonamide 2 TFA
  • HY-114672
    MBCQ
    		Inhibitor 99.80%
    MBCQ is a potent and selective cGMP-specific phosphodiesterase (PDE V; PDE5) inhibitor with an IC50 of 19 nM. MBCQ lacks inhibitory activity toward other PDE isozymes (all IC50s>100 μM). MBCQ dilates coronary arteries via specific inhibition of cGMP-PDE.
    MBCQ
  • HY-161853
    TX-2552
    		Inhibitor 99.69%
    TX-2552 is an orally active tyrosine DNA phosphodiesterase 1 (TDP1) inhibitor with an IC50 value of 0.62 μM. TX-2552 can enhance the clastogenic activity of Topotecan (HY-13768) in mouse bone marrow cells, as well as the anti-tumor effect of Topotecan (HY-13768) in Krebs-2 ascites tumor mice.
    TX-2552
  • HY-90009S
    Tadalafil-d3
    		Inhibitor 99.40%
    Tadalafil-d3 is the deuterium labeled Nortadalafil. Nortadalafil is demethyl Tadalafil, which is a PDE5 inhibitor, currently marketed in pill form for treating erectile dysfunction (ED) under the name Cialis; and under the name Adcirca for the treatment of pulmonary arterial hypertension.
    Tadalafil-d<sub>3</sub>
Cat. No. Product Name / Synonyms Application Reactivity
Phosphodiesterase (PDE) Isoform Comparison

Your Search Returned No Results.

Sorry. There is currently no product that acts on isoform together.

Please try each isoform separately.